Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

YOU might be full to bursting with food but, somehow, there’s always room for dessert. Your cravings for a sugar don’t mean you’re greedy – in fact, wanting a sweet treat ...

IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical ...

New research suggests that δ-receptor agonists regulate intestinal motility ... indicating the compound’s selective action on stress-induced intestinal dysfunction. In the Capsaicin-Induced ...

Glucagon-Like Peptide-1 Agonists (GLP-1s) Glucagon-like peptide-1 agonists (GLP-1s) can increase the release of insulin when blood sugar is rising and help with weight loss by making you feel full ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

Currently, there are two approved GLP-1 and one combined GIP/ GLP-1 receptor agonists indicated for chronic weight management. The advent of these treatments not only provide a vital tool in the ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

The pMDI was initially used for the administration of the non-selective beta-agonists ... action its use is now very limited. Over the last 10 years, the long-acting beta-agonists (LABAs) have ...